DAX25.421 +0,1%Est506.030 +0,2%MSCI World4.343 -0,1%Top 10 Crypto12,86 +6,2%Nas23.710 -0,1%Bitcoin81.081 +3,8%Euro1,1644 -0,2%Öl65,35 +1,6%Gold4.587 -0,2%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 TKMS thyssenkrupp Marine Systems TKMS00 NVIDIA 918422 Novo Nordisk A3EU6F Bayer BAY001 Deutsche Telekom 555750 DroneShield A2DMAA RENK RENK73 Siemens Energy ENER6Y BioNTech (ADRs) A2PSR2 Infineon 623100 Lufthansa 823212 SAP 716460 Allianz 840400 Amazon 906866
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Nach US-Inflationsdaten: US-Börsen letztlich schwach -- DAX schließt kaum verändert -- EZB-Ausblick: Zinserhöhung unwahrscheinlich -- Palantir, AMD, Intel, Google, BioNTech, Rüstungsaktien im Fokus
Top News
Ausblick: Citigroup legt die Bilanz zum abgelaufenen Quartal vor Ausblick: Citigroup legt die Bilanz zum abgelaufenen Quartal vor
Zcash nach Korrektur fast verdoppelt: Technische Signale stützen bullische Prognose Zcash nach Korrektur fast verdoppelt: Technische Signale stützen bullische Prognose
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Ipsen Aktie

Kaufen
Verkaufen
Ipsen Aktien-Sparplan
130,50 EUR +1,30 EUR +1,01 %
BMN
127,00 EUR -2,30 EUR -1,78 %
GVIE
Ipsen jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.10,54 Mrd. EUR

KGV26,49Div. Rendite1,26%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA0ESMG

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINFR0010259150

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolIPSEF

Ipsen Aktien News

DatumMeistgelesen
GlobeNewswireIpsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024)
GlobeNewswireIpsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance
GlobeNewswireIpsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2024
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2024
GlobeNewswireIpsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 27 - 2024
GlobeNewswireIpsen - June 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
GlobeNewswireHalf-year statement of IPSEN liquidity agreement - 2024 06 30
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2024
GlobeNewswireIpsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2024
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2024
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2024
GlobeNewswireIpsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
GlobeNewswireIpsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform
GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital
GlobeNewswireIpsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer   
GlobeNewswireIpsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis    
GlobeNewswireIpsen initiates a share buy-back program to cover its free employee share-allocation plan
GlobeNewswireIpsen announces the launch of an employee shareholding plan
GlobeNewswireAnnual General Meeting of Ipsen S.A. held on 28 May 2024
GlobeNewswireDescription of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at Ipsen S.A.’s Annual General Meeting on 28 May 2024
GlobeNewswireIpsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting
GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital
GlobeNewswireIpsen appoints Keira Driansky as EVP, President of North America
GlobeNewswireIpsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
GlobeNewswireIpsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
PR NewswireIpsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
PR NewswireIpsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
PR NewswireIpsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
GlobeNewswireIpsen publishes its 2023 Universal Registration Document
GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital
PR NewswireMarengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen
GlobeNewswireIpsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital
GlobeNewswireIpsen S.A. publishes its 2023 Consolidated Financial Statements
GlobeNewswireIpsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA  
GlobeNewswireBuilding on solid FY 2023 results, Ipsen anticipates four launches in 2024
GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital

Ipsen News

Ipsen News: auf dieser Seite finden Sie alle Ipsen News und Nachrichten zur Ipsen Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Ipsen News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Ipsen News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.